Literature DB >> 1741256

In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides.

J G Zendegui1, K M Vasquez, J H Tinsley, D J Kessler, M E Hogan.   

Abstract

Development of oligonucleotide derivatives as therapeutic agents requires an understanding of their pharmacokinetic behavior. The in vivo disposition and stability of a prototype of such compounds are reported here. The compound studied, a relatively G-rich 38 base 3' phosphopropyl amine oligonucleotide (TFO-1), was cleared from the circulation with a half-life of approximately 10 minutes, displaying distribution kinetics consistent with a two compartment model. TFO-1 was also readily absorbed into circulation from the peritoneal cavity. All tissues examined except brain accumulated the compound reaching concentrations calculated to be in the micromolar range. TFO-1 was found to be stable in circulation and in tissues in that a large fraction of intact material was detected 8 hours after injection, as assessed by gel electrophoresis. Approximately 20-30% of the injected dose was excreted in the urine over an 8 hour period. These results suggest that G-rich oligonucleotides, minimally modified at the 3' end, are relatively stable in vivo and have distribution kinetics favorable to use as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1741256      PMCID: PMC310371          DOI: 10.1093/nar/20.2.307

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  28 in total

1.  Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation.

Authors:  P A Beal; P B Dervan
Journal:  Science       Date:  1991-03-15       Impact factor: 47.728

2.  Modified deoxyoligonucleotides stable to exonuclease degradation in serum.

Authors:  J P Shaw; K Kent; J Bird; J Fishback; B Froehler
Journal:  Nucleic Acids Res       Date:  1991-02-25       Impact factor: 16.971

3.  Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice.

Authors:  T L Chen; P S Miller; P O Ts'o; O M Colvin; T L Chem
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

4.  Effect of preformed immune complexes on the clearance and tissue localization of single-stranded DNA in mice.

Authors:  W Emlen; M Mannik
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

5.  Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes.

Authors:  F M Orson; D W Thomas; W M McShan; D J Kessler; M E Hogan
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

6.  Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?

Authors:  L A Yakubov; E A Deeva; V F Zarytova; E M Ivanova; A S Ryte; L V Yurchenko; V V Vlassov
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

8.  Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels.

Authors:  E H Postel; S J Flint; D J Kessler; M E Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

9.  Binding of triple helix forming oligonucleotides to sites in gene promoters.

Authors:  R H Durland; D J Kessler; S Gunnell; M Duvic; B M Pettitt; M E Hogan
Journal:  Biochemistry       Date:  1991-09-24       Impact factor: 3.162

10.  A new and versatile reagent for incorporating multiple primary aliphatic amines into synthetic oligonucleotides.

Authors:  P S Nelson; R Sherman-Gold; R Leon
Journal:  Nucleic Acids Res       Date:  1989-09-25       Impact factor: 16.971

View more
  29 in total

1.  Synthesis and monitored selection of 5'-nucleobase-capped oligodeoxyribonucleotides.

Authors:  A A Mokhir; C Richert
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  A role for WRN in telomere-based DNA damage responses.

Authors:  Mark S Eller; Xiaodong Liao; SuiYang Liu; Kendra Hanna; Helena Bäckvall; Patricia L Opresko; Vilhelm A Bohr; Barbara A Gilchrest
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

3.  Characterization of aberrant melting peaks in unlabeled probe assays.

Authors:  Shale Dames; Rebecca L Margraf; David C Pattison; Carl T Wittwer; Karl V Voelkerding
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

Review 4.  Imaging oncogene expression.

Authors:  Archana Mukherjee; Eric Wickstrom; Mathew L Thakur
Journal:  Eur J Radiol       Date:  2009-03-04       Impact factor: 3.528

5.  Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination.

Authors:  H J Datta; P M Glazer
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

6.  Radiolabeled oligonucleotides for antisense imaging.

Authors:  Arun K Iyer; Jiang He
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 7.  Application of antisense DNA method for the study of molecular bases of brain function and behavior.

Authors:  S Ogawa; D W Pfaff
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

8.  Triplex formation with alpha anomers of purine-rich and pyrimidine-rich oligodeoxynucleotides.

Authors:  S B Noonberg; J C François; D Praseuth; A L Guieysse-Peugeot; J Lacoste; T Garestier; C Hélène
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

9.  Improved bioactivity of G-rich triplex-forming oligonucleotides containing modified guanine bases.

Authors:  Faye A Rogers; Janice A Lloyd; Meetu Kaushik Tiwari
Journal:  Artif DNA PNA XNA       Date:  2014

Review 10.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.